{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:11:03Z","timestamp":1791252663658,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":1193,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA031946"],"award-info":[{"award-number":["U10CA031946"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA033601"],"award-info":[{"award-number":["U10CA033601"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA180882"],"award-info":[{"award-number":["U10CA180882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA077597"],"award-info":[{"award-number":["U10CA077597"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10CA180791"],"award-info":[{"award-number":["U10CA180791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5U10CA180833"],"award-info":[{"award-number":["5U10CA180833"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UG1CA189960"],"award-info":[{"award-number":["UG1CA189960"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1093\/annonc\/mdw281","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:52:54Z","timestamp":1470703974000},"page":"1855-1860","source":"Crossref","is-referenced-by-count":102,"title":["Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma"],"prefix":"10.1016","volume":"27","author":[{"given":"M.A.","family":"Dickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Keohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Van Tine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw281_bb0010","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw281_bb0015","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw281_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw281_bb0025","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1634\/theoncologist.2009-0019","article-title":"Clinical experience with aurora kinase inhibitors: a review","volume":"14","author":"Boss","year":"2009","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw281_bb0030","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/MCB.02364-06","article-title":"MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy","volume":"27","author":"Hoar","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdw281_bb0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdw281_bb0040","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/ml500409n","article-title":"MLN8054 and Alisertib (MLN8237): discovery of selective oral Aurora A Inhibitors","volume":"6","author":"Sells","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1093\/annonc\/mdw281_bb0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1872312807666131229122359","article-title":"Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor Alisertib (MLN8237)","volume":"7","author":"Yang","year":"2014","journal-title":"Drug Metab Lett"},{"key":"10.1093\/annonc\/mdw281_bb0050","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.18632\/oncotarget.7335","article-title":"MLN-8237: a dual inhibitor of aurora A and B in soft tissue sarcomas","volume":"7","author":"Nair","year":"2016","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdw281_bb0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/0008-5472.CAN-10-1030","article-title":"Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase","volume":"71","author":"Chakravarty","year":"2011","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw281_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00259-001-0675-3","article-title":"[18F]FLT; portrait of a proliferation marker","volume":"29","author":"Mier","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdw281_bb0065","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw281_bb0070","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4161\/cc.11.4.19323","article-title":"The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent","volume":"11","author":"Nair","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1093\/annonc\/mdw281_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","article-title":"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","volume":"127","author":"Matulonis","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdw281_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000381917","article-title":"Outcomes of systemic therapy for patients with metastatic angiosarcoma","volume":"89","author":"D'Angelo","year":"2015","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdw281_bb0085","doi-asserted-by":"crossref","first-page":"686902","DOI":"10.1155\/2014\/686902","article-title":"Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre: reassessment in the era of ancillary molecular diagnosis","volume":"2014","author":"Thway","year":"2014","journal-title":"Sarcoma"},{"key":"10.1093\/annonc\/mdw281_bb0090","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/annonc\/mdr610","article-title":"Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions","volume":"23","author":"Ray-Coquard","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw281_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-10-150","article-title":"Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region","volume":"10","author":"Lurkin","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw281_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw281_bb0105","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trial","author":"Demetri","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw281_bb0110","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419359101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/10\/1855\/16698270\/mdw281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:53:20Z","timestamp":1624694000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419359101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0923753419359101"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw281","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}